Canaccord downgrades Intercept, lauds Alfasigma deal as “optimal outcome” (ICPT)


Intercept Pharmaceuticals, a biotech company listed on NASDAQ under the ticker symbol ICPT, has been downgraded to a hold rating by Canaccord Genuity. This downgrade comes after Intercept announced its agreement to be acquired by Alfasigma for $19 per share in cash. Canaccord believes that this deal is the best possible outcome for Intercept, as its drug obeticholic is no longer being pursued as a treatment for NASH (nonalcoholic steatohepatitis) and Oclavia, another drug in its portfolio, potentially faces strong competition in the near future.

Canaccord described the acquisition as a win-win situation for both Intercept and its investors. The $19 per share price offered by Alfasigma is only slightly below Canaccord’s 12-month price target of $20, leading the company to reduce its rating to hold. Canaccord now has a price target of $19 for Intercept.

Overall, the downgrade reflects Canaccord’s view that the acquisition by Alfasigma presents the best outcome for Intercept given the challenges it faces with its drug development pipeline.

Source link

Share post:




More like this

Google upgrades Bard chatbot with next-gen AI model Gemini in major update.

Google is updating its generative AI chatbot, Bard, with...

Apple to escape EU crackdown on iMessage under 13 words

The European Union is considering granting Apple Inc.'s iMessage...

GTA 6 Trailer boosts popularity of 70s rocker Tom Petty in streams

The highly anticipated trailer for Grand Theft Auto 6,...

Intel accuses AMD of selling ineffective CPUs in deleted attack

Intel has taken aim at AMD, accusing them of...